Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Yuichi Tambo, Takashi Sone, Koichi Nishi, Kazuhiko Shibata, Toshiyuki Kita, Tomoyuki Araya, Hiroki Shirasaki, Takahiro Shimizu, Taro Yoneda, Hiroki Matsuoka, Shigeki Nanjo, Hayato Koba, Nanao Terada, Tsukasa Ueda, Shunichi Nomura, Yuya Murase, Seiji Yano